Search results for "Cance"

showing 10 items of 12092 documents

γδ cell-based immunotherapy for cancer.

2019

Introduction: Cancer immunotherapy relies on the development of an efficient and long-lasting anti-tumor response, generally mediated by cytotoxic T cells. gamma delta T cells possess distinctive features that justify their use in cancer immunotherapy. Areas covered: Here we will review our current knowledge on the functions of human gamma delta T cells that may be relevant in tumor immunity and the most recent advances in our understanding of how these functions are regulated in the tumor microenvironment. We will also discuss the major achievements and limitations of gamma delta T cell-based immunotherapy of cancer. Expert opinion: Several small-scale clinical trials have been conducted i…

0301 basic medicineAdoptive cell transfergamma delta T celladoptive transfermedicine.medical_treatmentT cellClinical BiochemistryImmunotherapy Adoptive03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsDrug DiscoveryAnimalsHumansMedicineCytotoxic T cellcancertumor microenvironmentIntraepithelial LymphocytesPharmacologyTumor microenvironmentbusiness.industryCancerImmunotherapymedicine.diseaseClinical trial030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchcytotoxicitybusiness
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Factors Affecting Sexual Function and Body Image of Early-Stage Breast Cancer Survivors in Poland: A Short-Term Observation

2019

Abstract Introduction Knowing the important factors influencing sexual function and body image might facilitate the recovery process of breast cancer survivors. Surgery type, relationship quality, and partner support might be modified to create a space for psychosexual intervention. Patients and Methods This retrospective questionnaire-based study was performed on 128 women aged 18 to 65 years who were free of disease at time of study entry and who underwent surgical treatment for breast cancer. Diagnostic and Statistical Manual of Mental Disorders criteria were used to assessed female sexual dysfunction (FSD). Changes in Sexual Functioning Questionnaire (CSFQ) were used to measure sexual f…

0301 basic medicineAdultCancer Researchmedicine.medical_specialtyAdolescentbody imagebreast cancer survivorsmedicine.medical_treatmentMammaplastySexual BehaviorFemale sexual dysfunctionBreast NeoplasmsMastectomy Segmental03 medical and health sciencesYoung Adultdeterminant factors0302 clinical medicineBreast cancersurgery timeQuality of lifeCancer SurvivorsInternal medicineMedicineHumansMastectomyAgedRetrospective Studiesbusiness.industryOdds ratioMiddle Agedmedicine.disease030104 developmental biologySexual dysfunctionOncologysexual dysfunction030220 oncology & carcinogenesisQuality of LifeAnxietyFemalePolandmedicine.symptombusinessSexual functionMastectomyClinical Breast Cancer
researchProduct

Evaluation of serum CA 125 levels in patients with pelvic pain related to endometriosis.

2007

The aim of the study was to investigate the clinical value of the serum CA 125 level for diagnosing and determining the severity of endometriosis and pelvic pain associated with endometriosis. Eighty-six women who underwent operative laparoscopy were enrolled. Sixty-nine women with endometriosis and 17 without endometriosis participated in this study. In all of the patients, endometriosis was diagnosed and classified into stages according to the Revised American Fertility Society (R-AFS) classification. The mean serum CA 125 levels were determined in each patient. We also investigated the relationship between serum CA 125 concentration and the intensity of dysmenorrhea and dyspareunia in t…

0301 basic medicineAdultCancer Researchmedicine.medical_specialtyClinical BiochemistryCa 125 antigenEndometriosisEndometriosisPelvic PainSensitivity and SpecificityGastroenterologyAsymptomaticendometriosis ca125.Pathology and Forensic Medicine03 medical and health sciences0302 clinical medicineGynecologic Surgical ProceduresSettore MED/38 - Pediatria Generale E SpecialisticaDysmenorrheaStatistical significanceInternal medicineHumansMedicineIn patientGynecologybusiness.industryPelvic painMiddle Agedmedicine.disease030104 developmental biologyDyspareuniaOncology030220 oncology & carcinogenesisCA-125 AntigenClinical valueFemaleLaparoscopyOperative laparoscopymedicine.symptombusiness
researchProduct

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

2020

Background: Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. Materials and methods: We combined metabolomics, exosome circulating miRNAs and flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needle biopsy tumours to generate NAC-response predictive models. We also co-cultured and studied crosstalk between isolated patient…

0301 basic medicineAdultCancer Researchmedicine.medical_treatmentTriple Negative Breast NeoplasmsExosomesExosome03 medical and health sciences0302 clinical medicineImmune systemBreast cancerTriple-negative breast cancermicroRNABiomarkers TumorImmune ToleranceMedicineHumansIndoleamine-Pyrrole 23-DioxygenaseMetabolomicsProspective StudiesLiquid biopsyTriple-negative breast cancerCells CulturedAgedChemotherapybusiness.industryLiquid BiopsyTryptophanImmunosuppressionMiddle Agedmedicine.diseaseImmunohistochemistryCoculture TechniquesNeoadjuvant TherapyMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleNAC responsebusinessImmunosuppressionEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Epithelial-mesenchymal transition: a new target in anticancer drug discovery

2016

The conversion of cells with an epithelial phenotype into cells with a mesenchymal phenotype, referred to as epithelial-mesenchymal transition, is a critical process for embryonic development that also occurs in adult life, particularly during tumour progression. Tumour cells undergoing epithelial-mesenchymal transition acquire the capacity to disarm the body's antitumour defences, resist apoptosis and anticancer drugs, disseminate throughout the organism, and act as a reservoir that replenishes and expands the tumour cell population. Epithelial-mesenchymal transition is therefore becoming a target of prime interest for anticancer therapy. Here, we discuss the screening and classification o…

0301 basic medicineAdultEpithelial-Mesenchymal TransitionCellPopulationAntineoplastic AgentsPharmacologyBiology03 medical and health sciences0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALENeoplasmsDrug DiscoverymedicineHumanscancerEpithelial–mesenchymal transitioneducationAdult; Antineoplastic Agents; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Drug Discovery; Pharmacology; Drug Discovery3003 Pharmaceutical SciencePharmacologyeducation.field_of_studyTransition (genetics)Drug discoveryDrug Discovery3003 Pharmaceutical ScienceGeneral MedicineAnticancer drugEMT target therapy chemoresistance030104 developmental biologymedicine.anatomical_structureDrug developmentApoptosis030220 oncology & carcinogenesisCancer research
researchProduct

Occupational Heat Exposure and Breast Cancer Risk in the MCC-Spain Study.

2021

Background: Mechanisms linking occupational heat exposure with chronic diseases have been proposed. However, evidence on occupational heat exposure and cancer risk is limited. Methods: We evaluated occupational heat exposure and female breast cancer risk in a large Spanish case-control study. We enrolled 1,738 breast cancer cases and 1,910 frequency-matched population controls. A Spanish job exposure matrix, MatEmEsp, was used to assign estimates of the proportion of workers exposed (P greater than or equal to 25% for at least one year) and work time with heat stress (wet bulb globe temperature ISO 7243) for each occupation. We used three exposure indices: ever vs. never exposed, lifetime c…

0301 basic medicineAdultHot TemperatureEpidemiologyPopulationJob-exposure matrixCumulative ExposureBreast NeoplasmsDisease03 medical and health sciences0302 clinical medicineBreast cancerRisk FactorsEnvironmental healthOccupational ExposureMedicineHumanseducationAgedAged 80 and overeducation.field_of_studybusiness.industryConfoundingOdds ratioMiddle Agedmedicine.diseaseConfidence intervalOccupational Diseases030104 developmental biologyOncologySpain030220 oncology & carcinogenesisCase-Control StudiesFemalebusiness
researchProduct

Succinate receptor mediates intestinal inflammation and fibrosis.

2018

Succinate, an intermediate of the tricarboxylic acid cycle, is accumulated in inflamed areas and its signaling through succinate receptor (SUCNR1) regulates immune function. We analyze SUCNR1 expression in the intestine of Crohn's disease patients and its role in murine intestinal inflammation and fibrosis. We show that both serum and intestinal succinate levels and SUCNR1 expression in intestinal surgical resections were higher in CD patients than in controls. SUCNR1 co-localized with CD86, CD206, and alpha-SMA(+) cells in human intestine and we found a positive and significant correlation between SUCNR1 and alpha-SMA expression. In human isolated fibroblasts from CD patients SUCNR1 expres…

0301 basic medicineAdultMaleAdolescentImmunologyMacrophage polarizationSuccinic Acid610 Medicine & healthProinflammatory cytokineReceptors G-Protein-Coupled03 medical and health sciencesMiceYoung Adult0302 clinical medicineImmune systemCrohn DiseaseFibrosismedicineImmunology and AllergyAnimalsHumansIntestinal MucosaFibroblastReceptorCells CulturedCD86InflammationMice Knockout2403 Immunologybusiness.industryMacrophagesmedicine.diseaseColitisFibrosisCitric acid cycleMice Inbred C57BLDisease Models Animal10219 Clinic for Gastroenterology and Hepatology030104 developmental biologymedicine.anatomical_structure2723 Immunology and AllergyCancer researchFemalebusiness030215 immunologyMucosal immunology
researchProduct

Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.

2019

Involvement of sex hormones in colorectal cancer (CRC) development has been linked to oestrogen receptor β (ERβ). Expression of ERβ is found reduced in tumour tissue and inversely related to mortality. However, mechanisms are not well understood. Our study aimed to detect differentially methylated genes associated with ERβ expression, which could point to mechanisms by which ERβ could influence risk and prognosis of CRC. Epigenome-wide DNA methylation profiling was performed using Illumina HumanMethylation450k BeadChip arrays in two independent tumour sample sets of CRC patients recruited in 2003–2010 by the German DACHS study (discovery cohort n = 917, replication cohort n = 907). ERβ expr…

0301 basic medicineAdultMaleCancer ResearchColorectal cancerBiologyGenomeEpigenesis Genetic03 medical and health sciencesTumour tissue0302 clinical medicinemedicineBiomarkers TumorEstrogen Receptor betaHumansEpigeneticsOestrogen receptorBeta (finance)Promoter Regions GeneticMolecular BiologyAgedAged 80 and overDNA MethylationMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticSurvival Rate030104 developmental biology030220 oncology & carcinogenesisCase-Control StudiesDNA methylationCancer researchFemaleColorectal NeoplasmsHormoneFollow-Up StudiesGenome-Wide Association StudyResearch PaperEpigenetics
researchProduct